A Randomized Phase II Study to Evaluate the Efficacy and Safety of Chemotherapy (CT) vs Androgen Deprivation Therapy (ADT) in Patients With Recurrent and/or Metastatic, Androgen Receptor (AR) Expressing, Salivary Gland Cancer (SGCs)
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 149
- 试验地点
- 26
- 主要终点
- Response rate (RR)
研究概览
简要总结
Salivary Gland (SG) Cancers are a rare and heterogeneous group of tumors, usually approached by multidisciplinary teams in high specialized centers. Until today no standard of care exists to treat these cancers. The identification of a target, the androgen receptor, in SG tumors has allowed for new treatment strategies options for this rare group of diseases. As a matter of fact, strong positivity for androgen expression has been found in salivary duct carcinoma and adenocarcinomas. The purpose of this study is therefore to evaluate the efficacy and safety of chemotherapy versus androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic AR expressing SGCs.
The study will include two cohorts of patients: Cohort A, which comprises chemo-naïve patients, and Cohort B, which comprises pretreated patients.
详细描述
Patients in Cohort A will be randomized 1:1 at the study entry to receive ADT (triptorelin + bicalutamide 50 mg) or standard chemotherapy. Patients of Cohort A randomized to the control arm (chemotherapy arm) will be given the option to enter Cohort B at the time of disease progression. As long as Cohort A is open to recruitment, patients who will be treated by chemotherapy will be simultaneously enrolled in Cohort B. Accrual in Cohort B will be stopped when recruitment of 76 eligible patients in Cohort A is reached.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically proven diagnosis of recurrent and/or metastatic salivary duct cancer; adenocarcinoma, NOS; and AR expression in at least 70% of nuclei of neoplastic cells based on central review
- •Sufficient tissue must be available either historically or a biopsy must be done as a part of this study and sent to central review for patients enrolled in both cohorts
- •Presence of at least one uni-dimensional measurable lesion by CT-scan or MRI according to RECIST criteria version 1.1 (target lesion).
- •Patients older than 18 years old;
- •Performance Status ECOG 0-1;
- •Adequate bone marrow function:
- •WBC ≥ 3.5/10exp9L
- •absolute neutrophil count ≥ 1,5x10exp9/L
- •hemoglobin > 9 g/dL
- •platelet count ≥ 100x10exp9/L
- •Adequate liver function:
- •AST < 2.5 times upper limit of normal
- •ALT < 2.5 times upper limit of normal
- •bilirubin < 1.5 times upper limit of normal
- •the concomitant evidence of AST < 2.5 times upper limit of normal, ALT < 2.5 times upper limit of normal and bilirubin > 1.5 times upper limit of normal is not allowed
- •Adequate renal function:
- •serum creatinine level (≤ 1.3 mg/dL)
- •calculated creatinine clearance ≥ 60 mL/min based on the standard Cockcroft and Gault formula
- •Adequate cardiac function as demonstrated by a clinically normal 12 lead ECG; additionally for patients who will receive Cisplatin and Doxorubicin adequate cardiac function should be demonstrated by a left ventricular ejection fraction (LVEF) ≥ 50% (within 2 weeks prior to treatment start)
排除标准
- •Actively bleeding tumor if the patient is intended to be treated with carboplatin
- •Patients with bone disease or brain disease as the sole disease site; brain metastases are allowed in case of systemic disease, but must have been treated at least 4 weeks before enrollment and must be stable after that;
- •recent history of congestive heart failure, unstable angina within the past 3 months, cardiac arrhythmia, myocardial infarction, congenital long QTc prolongation, stroke, TIA within the past 6 months;
- •previous cardiac toxicity induced by another anthracycline or previous exposure to maximum cumulative dose of another anthracycline if the patient is intended to be treated with doxorubicin
- •history of allergic reactions attributed to compounds of similar chemical or biological composition to cis/carboplatin, paclitaxel, doxorubicin, bicalutamide or triptorelin;
- •concomitant medications with terfenadine, astemizole, cisaprid
- •use of phenytoin
- •Patients who received vaccine for yellow fever
- •active second malignancy during the last five years except non melanomatous skin cancer or carcinoma in situ of the cervix;
- •positive serum pregnancy test within 1 week prior to the first dose of study treatment for Women of child bearing potential (WOCBP);
- •no adequate birth control measures, as defined by the investigator, during the study treatment period and for at least 6 months after the last study treatment for patients of childbearing / reproductive potential.
- •psychological, familiar, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;
- •written informed consent not given according to ICH/GCP, and national/local regulations, before patient registration
- •participation in another interventional clinical trial in the preceding 4 weeks prior to randomization
- •for cohort A patients: previous chemotherapy for recurrent/metastatic disease (previous chemotherapy given concomitantly with RT in the past is allowed, including cisplatin but it should be completed at least 6 months before enrollment).
研究组 & 干预措施
Chemotherapy
Chemotherapy = either Cisplatin + Doxorubicin or Carboplatin + Paclitaxel
Patients from cohort A (chemonaïve) may be randomized in this arm to receive chemotherapy
干预措施: Cisplatin + Doxorubicin (Drug)
Chemotherapy
Chemotherapy = either Cisplatin + Doxorubicin or Carboplatin + Paclitaxel
Patients from cohort A (chemonaïve) may be randomized in this arm to receive chemotherapy
干预措施: Carboplatin + Paclitaxel (Drug)
Androgen Deprivation Therapy (ADT)
ADT = bicalutamide + triptorelin
Patients from cohort A (chemonaive) may be randomized to receive ADT, and patients from cohort B (pre-treated) will receive ADT without having been randomized.
干预措施: bicalutamide + triptorelin (Drug)
结局指标
主要结局
Response rate (RR)
时间窗: 37 months after First Patient In
RR is a primary outcome for cohort B
Progression Free Survival (PFS)
时间窗: 37 months after First Patient In
PFS is a primary outcome for cohort A
次要结局
- Response Rate (RR)(37 months after First Patient In)
- Progression Free Survival (PFS)(37 months after First Patient In)